| Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy R AJ, C V, B T, V P, C S, van Lunzen J, C GM, E V, G AM, B A, A D, V P, ... JAMA 316 (2), 171-81, 2016 | 1834 | 2016 |
| Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of … AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, O Degen, ... The Lancet 393 (10189), 2428-2438, 2019 | 1183 | 2019 |
| Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression S Swindells, JF Andrade-Villanueva, GJ Richmond, G Rizzardini, ... New England Journal of Medicine 382 (12), 1112-1123, 2020 | 499 | 2020 |
| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 … P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ... The Lancet 393 (10167), 143-155, 2019 | 444 | 2019 |
| Antifungal drug resistance to azoles and polyenes MM Canuto, FG Rodero The Lancet infectious diseases 2 (9), 550-563, 2002 | 439 | 2002 |
| Evaluation of the Immunochromatographic Binax NOW Assay for Detection of Streptococcus pneumoniae Urinary Antigen in a Prospective Study of Community … F Gutiérrez, M Mar, JC Rodríguez, A Ayelo, B Soldán, L Cebrián, C Mirete, ... Clinical Infectious Diseases 36 (3), 286-292, 2003 | 352 | 2003 |
| Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index M Masiá, F Gutierrez, C Shum, S Padilla, JC Navarro, E Flores, ... Chest 128 (4), 2223-2229, 2005 | 310 | 2005 |
| Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring F Gutiérrez, A Navarro, S Padilla, R Antón, M Masiá, J Borrás, ... Clinical infectious diseases 41 (11), 1648-1653, 2005 | 289 | 2005 |
| The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens F Gutiérrez, M Masiá, C Mirete, B Soldán, JC Rodríguez, S Padilla, ... Journal of infection 53 (3), 166-174, 2006 | 286 | 2006 |
| Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study E Martinez, M Larrousse, JM Llibre, F Gutierrez, M Saumoy, A Antela, ... Aids 24 (11), 1697-1707, 2010 | 244 | 2010 |
| Dalbavancin in the treatment of different gram-positive infections: a real-life experience E Bouza, M Valerio, A Soriano, L Morata, EG Carus, ... International journal of antimicrobial agents 51 (4), 571-577, 2018 | 161 | 2018 |
| Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study J García-Abellán, S Padilla, M Fernández-González, JA García, V Agulló, ... Journal of clinical immunology 41 (7), 1490-1501, 2021 | 153 | 2021 |
| Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir E Martínez, PM D'Albuquerque, JM Llibre, F Gutierrez, D Podzamczer, ... AIDS 26 (18), 2315-26, 2012 | 143 | 2012 |
| Long-acting injectable cabotegravir+ rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials G Rizzardini, ET Overton, C Orkin, S Swindells, K Arasteh, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 85 (4), 498-506, 2020 | 133 | 2020 |
| Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain F Gutierrez, M Masia, JC Rodriguez, C Mirete, B Soldán, S Padilla, ... Clinical microbiology and infection 11 (10), 788-800, 2005 | 124 | 2005 |
| Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy M Masiá, S Padilla, D Alvarez, JC Lopez, I Santos, V Soriano, ... Aids 27 (2), 181-189, 2013 | 110 | 2013 |
| Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens F Gutiérrez, S Padilla, A Navarro, M Masiá, I Hernández, J Ramos, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 33 (5), 594-600, 2003 | 107 | 2003 |
| Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients M Masiá, S Padilla, E Bernal, MV Almenar, J Molina, I Hernández, ... Clinical Therapeutics 29 (7), 1448-1455, 2007 | 103 | 2007 |
| Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk JM Gatell, L Assoumou, G Moyle, L Waters, M Johnson, P Domingo, J Fox, ... Aids 31 (18), 2503-2514, 2017 | 101 | 2017 |
| A bibliometric analysis of tuberculosis research indexed in PubMed, 1997–2006 JM Ramos, S Padilla, M Masia, F Gutierrez The International Journal of Tuberculosis and Lung Disease 12 (12), 1461-1468, 2008 | 101 | 2008 |
Félix Gutiérrez RoderoHospital Universitario de Elche & Universidad Miguel Hernández, Alicante, SpainVerificeret mail på gva.es